Balancing dose preservation and treatment efficiency in motion-managed magnetic resonance image-guided radiotherapy of pancreatic cancer
Authors:
- Uffe BernchouUBUffe Bernchou
- Carsten BrinkCBCarsten Brink
- Rana BahijRBRana Bahij
- Anders S. BertelsenABAnders S. Bertelsen
- Tine SchytteTSTine Schytte
- Faisal MahmoodFMFaisal Mahmood
Open Access
- 15 February 2026
- journal article
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 37
Abstract
No abstract availableKeywords
Funding Information
- Elekta
This publication has 44 references indexed in Scilit:
- Performance characterization of a novel hybrid dosimetry insert for simultaneous spatial, temporal, and motion‐included dosimetry for MR‐linacMedical Physics, 2023
- Impact of abdominal compression on intra-fractional motion and delivered dose in magnetic resonance image-guided adaptive radiation ablation of adrenal gland metastasesPhysica Medica, 2023
- Trends in pancreatic cancer incidence, characteristics, and outcomes in Denmark 1980–2019: A nationwide cohort studyCancer Epidemiology, 2022
- Estimated Projection of US Cancer Incidence and Death to 2040JAMA Network Open, 2021
- Quantitative analysis of MRI‐guided radiotherapy treatment process time for tumor real‐time gating efficiencyJournal of Applied Clinical Medical Physics, 2020
- Using adaptive magnetic resonance image‐guided radiation therapy for treatment of inoperable pancreatic cancerCancer Medicine, 2019
- MR-guided Gated Stereotactic Radiation Therapy Delivery for Lung, Adrenal, and Pancreatic Tumors: A Geometric AnalysisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2018
- First clinical implementation of real‐time, real anatomy tracking and radiation beam controlMedical Physics, 2018
- Dosimetric validation of a magnetic resonance image gated radiotherapy system using a motion phantom and radiochromic filmJournal of Applied Clinical Medical Physics, 2017
- Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without ErlotinibJAMA, 2016